Bicara Therapeutics Inc. announced multiple presentations at the AACR Annual Meeting 2025 regarding their leading therapy, ficerafusp alfa, a novel bifunctional antibody targeting EGFR and TGF-β for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results